Option chain shows key data for GMexico Transportes's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for GMexico Transportes.

GMexico Transportes (OTC:GMXTF) Stock, Option Chain

GMexico Transportes SAB de CV is engaged in copper production, rail transportation, and infrastructure businesses.

GMEXICO TRANSPORTES SAB by GMexico Transportes SAB de CV

GMexico Transportes SAB de CV

Barclays analyst Raimo Lenschow maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Overweight and lowers the price target from $314 to $305.

News

Price Target

Analyst Ratings

WDAY

Barclays Maintains Overweight on Workday, Lowers Price Target to $305

Cansortium Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TIUM#CSE">TIUM</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTCQB">CNTMF</a>) announced on Tuesday that it has secured a new senior secured credit agreement of up to $96.5 million with Chicago Atlantic Admin, LLC, as an administrative agent for certain lenders.
The Tampa, Florida-based vertically integrated cannabis company operating under the FLUENT brand, said the credit agreement includes a 12% cash interest rate and 1% paid-in-kind interest annually. It matures on November 26, 2028, with no material debt maturities until then.
"We are excited to announce the successful completion of our senior secured refinancing," Robert Beasley, CEO of Cansortium, said. "The loan's favorable interest rate and single financial covenant underscore our strong financial standing, while its non-dilutive structure &#8211; free of equity or warrants&nbsp;– preserves shareholder value."
Read Also: <a href="https://www.benzinga.com/24/11/42111313/exclusive-fluent-launches-new-cannabis-concentrates-line-for-medical-marijuana-patients-in-florida">FLUENT Launches New Cannabis Concentrates Line For Medical Marijuana Patients In Florida</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
The company plans to refinance its existing $71 million senior secured term loan, which was set to mature on May 29, 2025. As part of this refinancing, Cansortium has removed a previously required $10 million prepayment obligation that would have been triggered upon completing its planned merger with RIV Capital Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#CSE">RIV</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>). 
Cansortium expects that the merger with RIV Capital -which operates the Etain brand in New York- will be <a href="https://www.benzinga.com/markets/cannabis/24/08/40605119/riv-capital-and-cansortium-shareholders-approve-merger-combined-weed-company-will-operate-in-fou">wrapped up in early December 2024</a>.
RIV reported a 111% year-over-year increase in second-quarter net revenue to <a href="https://www.benzinga.com/markets/cannabis/24/08/40602481/riv-capitals-111-revenue-surge-amid-ny-expansion-prepares-for-major-merger-with-cansortium-canna">$3.8 million in August</a>. In a subsequent, October update, the company said third-quarter marked "a turning point for RIV Capital and its shareholders as the team translated strategy and execution into a record-setting year."
Beasley said the financing also provides $25 million in additional credit lines for real estate and acquisitions, positioning Cansortium for growth in Pennsylvania, New York and other emerging markets.
In the meantime, Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) – a cannabis consumer packaged goods company and owner of&nbsp;RISE Dispensaries – said Wednesday that it has received principal and cash interest payments&nbsp;related to a prior loan to Cansortium.
"Following Cansortium's recent financing, Green Thumb received approximately $23 million of principal plus 13% accrued interest, adding to its Q3 ending cash balance of $174 million," Green Thumb said in a press release.
Ben Kovler, Green Thumb's chairman and CEO, praised Cansortium's move.
"This investment is a good example of our opportunistic style to allocating capital &#8211; we want to have upside optionality combined with downside protection," Kovler said. "The result in this case of getting paid back 100 cents on the dollar feels like a win. We look forward to re-allocating these dollars into unique opportunities within our circle of competence to benefit shareholders."&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41282624/major-cannabis-merger-approved-in-new-york-can-weed-stock-investors-take-advantage">Major Cannabis Merger Approved In New York: Can Weed Stock Investors Take Advantage?</a></li>
</ul>

Cannabis

Financing

CNPOF

CNTMF

CSE:GTII

CSE:RIV

CSE:TIUM

GTBIF

GTII

Cannabis Co. Cansortium Refinances Debt With $96.5M Loan Ahead Of Major Merger And Next Phase Of Growth

Tigress Financial analyst Ivan Feinseth maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Buy and raises the price target from $85 to $135.

TWLO

Tigress Financial Maintains Buy on Twilio, Raises Price Target to $135

Trading Ideas

Top KingWin Shares Halted On Circuit Breaker To The Upside, Stock Now Up 233.3%

Barclays analyst Adrienne Yih maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and raises the price target from $43 to $51.

URBN

Barclays Maintains Overweight on Urban Outfitters, Raises Price Target to $51

Unusual Machines, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading higher on Wednesday.</a>
The US-based drone and drone components manufacturer has made a notable move to strengthen its position in the growing drone industry by announcing the appointment of<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42213315/donald-trump-jr-joins-unusual-machines-as-an-advisor" rel="noreferrer noopener"> </a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42213315/donald-trump-jr-joins-unusual-machines-as-an-advisor" rel="noreferrer noopener">Donald Trump Jr.</a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42213315/donald-trump-jr-joins-unusual-machines-as-an-advisor" rel="noreferrer noopener"> to its advisory board.</a>
Trump Jr., a renowned business leader, best-selling author, and investor in the company, brings significant expertise to the board.
His appointment comes at a &#8220;pivotal time&#8221; as the company is working to bring drone component manufacturing back to the U.S.
Allan Evans, CEO of Unusual Machines, emphasized Trump Jr.&#8217;s wealth of experience, which will be invaluable as the company expands its business.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42210528/us-stock-futures-signal-a-muted-open-smallcaps-may-advance-analyst-flags-cross-asset-volatility" rel="noreferrer noopener">Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The &#8216;Stronger Times Of The Year For Stocks&#8217;</a>
&#8220;The need for drones is obvious. It is also obvious that we must stop buying Chinese drones and Chinese drone parts,&#8221; said Donald Trump Jr. &#8220;I love what Unusual Machines is doing to bring drone manufacturing jobs back to the USA and am excited to take on a bigger role in the movement.&#8221;
Unusual Machines has been making strides in this direction, having recently launched the Brave F7 FPV Flight Controller, a product that underscores the company&#8217;s commitment to reducing dependence on foreign-made drone parts.
Financially, the company showed strong performance, with third-quarter sales reaching approximately $1.53 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac41988898/unusual-machines-issues-letter-to-shareholders" rel="noreferrer noopener">marking a 9% increase from the previous quarter.</a> With a gross margin of 26%, the company remains on track to meet its target of $5 million in sales for 2024.
The company also plans to expand its Rotor Riot operations, introduce new U.S.-made components, and increase enterprise sales in the coming months.
Price Action: UMAC shares are trading higher by 84% to $9.86 at last check Wednesday.
Read next:&nbsp;
<ul>
<li><a href="http://jd%20vance's%20investment%20playbook%20has%20bitcoin%20and%20etfs:%20Here's%20What%20Else%20The%20VP-Elect%20Is%20Betting%20On/" target="_blank" rel="noreferrer noopener">JD Vance's Investment Playbook Has Bitcoin And ETFs: Here's What Else The VP-Elect Is Betting On</a></li>
</ul>
Image: Shutterstock/ Dmitry Kalinovsky

Equities

Management

Markets

Movers

General

UMAC

Why Is Drone Company Unusual Machines Stock Skyrocketing Today?

SOS American Depositary Shares Halted On Circuit Breaker To the Upside, Stock Now Up 54.7%

RADX

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and raises the price target from $603 to $655.

Barclays Maintains Overweight on UnitedHealth Group, Raises Price Target to $655

Barclays analyst Tim Long maintains Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Overweight and raises the price target from $75 to $87.

NTNX

Barclays Maintains Overweight on Nutanix, Raises Price Target to $87

Unusual Machines Shares Resume Trade

POSaBIT Systems Corporation (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/POSAF#OTCQX">POSAF</a>), a provider of payments and point-of-sale infrastructure for the cannabis industry, reported Tuesday its financial results for the three months ended Sept. 30, 2024. Revenue for the quarter was $4.08 million, reflecting a 70% year-over-year decline primarily due to temporary disruptions in transaction processing, which has now been restored to 75% of pre-disruption levels, management said. Despite the revenue drop, the company achieved a higher gross profit margin of 40%, up from 23% in the same quarter of last year.
"We are pleased to report another solid performance in the third quarter, highlighted by our continuation of positive adjusted EBITDA, growing adjusted EBITDA quarter over quarter by 53%," said Ryan Hamlin, co-founder and CEO of POSaBIT. "Additionally, we are excited to report that POSaBIT's new eCommerce menu capability for our POS merchants is getting great reviews, with nearly 40 new merchants in the last 90 days. We expect by next year at this time, we will have over 200 merchants using the POSaBIT eCommerce menu."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42116007/cannabis-fintech-posabit-integrates-metrc-connect-reporting">Cannabis Fintech POSaBIT Integrates Metrc Connect Reporting</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Q3 Financial Highlights</h2>
<ul>
<li>Gross profit was $1.63 million compared to $3.19 million in the comparable quarter of last year.</li>
<li>Gross profit margin was 40% compared to 23% in the third quarter of 2023.</li>
<li>Operating costs amounted to $3.37 million compared to $3.45 million in the same quarter of the prior year.</li>
<li>Loss was $2.08 million compared to $7.49 million in the corresponding period of 2023.</li>
<li>Adjusted EBITDA was a gain of $148,128 compared to an adjusted EBITDA loss of $32,622 in the third quarter of last year.</li>
<li>As of September 30, 2024, the company had cash on hand and cash equivalents of $900,000, slightly down quarter over quarter.</li>
</ul>
<h2 class="wp-block-heading">Recent Operational Highlights</h2>
<ul>
<li>Restored transaction processing levels to 75% of pre-disruption levels.</li>
<li>Implemented cost reduction program with ~$4 million of annual savings.</li>
<li>Intends to apply to list its common shares on the TSXV.</li>
<li>Ranked 132nd on the Deloitte Technology Fast 500, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America.</li>
</ul>
"In alignment with our commitment to operational excellence, we recently initiated a comprehensive cost reduction program aimed at driving efficiencies across our business, with the ultimate goal of achieving profitability," Hamlin continued. "Additionally, we announced our intention to apply to list on the TSXV in order to facilitate ownership of our shares and improve trading liquidity. As we approach 2024, I am genuinely excited about the strategic initiatives and opportunities that lie ahead for POSaBIT."
<h2 class="wp-block-heading">Price Action</h2>
POSaBIT shares are trading at $0.077 on Wednesday morning, only 0.32% below Tuesday&#8217;s closing price.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">Canadian Cannabis Co. Decibel Reports 12% YoY Drop In Q3 Revenue But Increases Gross Margin To 53%</a></li>
</ul>
Photo: Courtesy of Bigc Studio via Shutterstock

Earnings

POSAF

Cannabis Fintech POSaBIT Systems Q3 Revenue Plunges Amid Temporary Processing Disruptions, But Gross Profit Margins Surge

Barclays analyst Tim Long maintains HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) with a Equal-Weight and raises the price target from $32 to $35.

Barclays Maintains Equal-Weight on HP, Raises Price Target to $35

Unusual Machines Shares Halted On Circuit Breaker To The Downside, Stock Now Up 75.8%

Peloton Interactive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NYSE">PTON</a>) short percent of float has fallen 7.42% since its last report. The company recently reported that it has 59.95 million shares sold short, which is 18.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Peloton Interactive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732717822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Peloton Interactive has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Peloton Interactive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Peloton Interactive's peer group average for short interest as a percentage of float is 7.15%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PTON

How Is The Market Feeling About Peloton Interactive?

Semtech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NYSE">SMTC</a>) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 6.55 million shares sold short, which is 11.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Semtech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732717816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Semtech has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Semtech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Semtech's peer group average for short interest as a percentage of float is 10.40%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SMTC

Peering Into Semtech's Recent Short Interest

LPL Finl Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NYSE">LPLA</a>) short percent of float has risen 19.67% since its last report. The company recently reported that it has 1.08 million shares sold short, which is 1.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>LPL Finl Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732717811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for LPL Finl Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing LPL Finl Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, LPL Finl Hldgs's peer group average for short interest as a percentage of float is 3.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LPLA

How Is The Market Feeling About LPL Finl Hldgs?

Barclays analyst Tim Long maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Equal-Weight and raises the price target from $106 to $115.

DELL

Barclays Maintains Equal-Weight on Dell Technologies, Raises Price Target to $115

Outlook Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42210551/outlook-therapeutics-announces-preliminary-topline-results-of-norse-eight-clinical-trial" rel="noreferrer noopener">wet AMD patients</a>.
In the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified noninferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA.
The pre-specified noninferiority endpoint was measured by mean change in best corrected visual acuity (BCVA) from baseline to week 8.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?</a>
The difference in the means between the ONS-5010 and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Lucentis (ranibizumab) in the NORSE EIGHT trial was -2.257 BCVA letters, while the lower bound of the pre-specified noninferiority margin in the SPA was -3.5; the hypothesis of noninferiority was not met (p&gt;0.025).&nbsp;
In the intent-to-treat (ITT) primary dataset, NORSE EIGHT demonstrated a mean +4.2 letter improvement in BCVA in the ONS-5010 arm and +6.3 letter improvement in BCVA in the ranibizumab arm.
However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010.
Data analysis is ongoing as month 3 data from NORSE EIGHT are being collected. The data is expected to be available in January 2025.
Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, Outlook Therapeutics plans to resubmit the U.S. marketing application for ONS-5010 in the first quarter of calendar 2025.
ONS-5010/Lytenava (bevacizumab gamma) has already been granted Marketing Authorization in the European Union and the U.K.
Outlook Therapeutics intends to continue efforts to launch in Europe in 2025, either directly or with a licensing partner.
If approved by the FDA, Outlook Therapeutics plans to commercialize ONS-5010/Lytenava (bevacizumab-vikg) directly in the U.S. It is also assessing partnering options for Lytenava (bevacizumab gamma) in Europe and other regions <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40706252/outlook-therapeutics-announces-completion-of-enrollment-in-norse-eight-clinical-trial" rel="noreferrer noopener">outside of the U.S.</a>
Price Action: OTLK stock is down 80% at $0.97 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42213279/whats-going-on-with-us-listed-chinese-stocks-alibaba-jd-nio-li-xpeng-on-wednesday-2" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With US Listed Chinese Stocks Alibaba, JD, Nio, Li, XPeng On Wednesday?</a></li>
</ul>
Photo by Amanda Dalbjörn on Unsplash.

Biotech

Health Care

OTLK

RHHBY

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

TD Cowen analyst Marc Bianchi reiterates TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Buy and maintains $37 price target.

Comments

GMexico Transportes

GMexico Transportes (GMXTF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga